Ophthalmology

DOT spectacle lenses slow 12‑month axial elongation in Chinese children

In a randomized trial of 195 Chinese myopic children aged 6–13, diffusion optics technology (DOT) spectacles reduced 12‑month axial elongation versus single‑vision lenses by -0.26 mm (P<0.0001). Mean AL change was 0.09 mm for DOT versus 0.35 mm for single‑vision; cSER progression difference was 0.48 D favoring DOT. No severe adverse events were reported during the 12‑month interim analysis. Results support DOT lenses as an effective myopia‑control option in this age group, pending full 24‑month outcomes. 1

Two‑trial paradigm shows nontrivial discrepancies and inconsistent FDA handling

Among 9,925 phase 3 trials, 498 duplicates formed 246 pairs/triplets, with discrepant statistical conclusions in 35 pairs (17%). FDA approved 14 drugs despite discrepant trial conclusions and required additional RCTs in eight cases. Outcome changes and type I error modifications occurred in a minority of duplicated trials, sometimes after unblinding. Findings highlight regulatory inconsistency when paired pivotal trials diverge. 2

Predictors of 12‑month vision after fovea‑involving submacular hemorrhage

In a prospective cohort of 75 Asian eyes with fovea‑involving SMH, mean BCVA improved from 1.04 to 0.69 logMAR at 12 months with standard anti‑VEGF therapy. Multivariable analysis identified younger age, better baseline BCVA, and thicker subfoveal choroid as independent predictors of good outcome. Larger hemorrhage area independently predicted poor outcome (OR 1.04 per mm²). Use these predictors to counsel prognosis and individualize expectations after SMH. 3